[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean disease-free survival time was 18.6 +/- 6.7 months (95% CI: 5.4-31.8).
  • Loco-regional, intra-abdominal lymph node, peritoneum, bone, brain recurrences were also seen in one patient each.
  • The mean survival after recurrence was 19.0 +/- 3.3 months (95% CI: 12.6-25.5), and the 50% survival was 18.4 months with mitotan and cytotoxic drug therapy.
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


2. Morita S, Matsuda Y, Oshima T, Kubota T, Kawauchi Y, Kobayashi M, Nomoto M, Aoyagi Y: [Case of extra-hepatic lymph node metastasis of hepatocellular carcinoma with no evident sign of intra-hepatic recurrence]. Nihon Shokakibyo Gakkai Zasshi; 2009 Mar;106(3):397-404
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of extra-hepatic lymph node metastasis of hepatocellular carcinoma with no evident sign of intra-hepatic recurrence].
  • A 73-year-old man with chronic hepatitis C was Successfully treated for hepatocellular carcinoma (HCC) by localized treatment.
  • During the follow-up period, abdominal computed tomography (CT) revealed no HCC recurrence in the liver.
  • However, 9 months after the treatment, abdominal lymph nodes appeared enlarged on CT.
  • Laparoscopic biopsy of the lymph nodes showed that the lesion was HCC, and TS-1/cisplatin chemotherapy was performed.
  • However, extra-hepatic lymph nodes rapidly grew, leading to obstructive jaundice and finally death 10 months after of HCC metastasis.
  • Although abdominal lymph node metastasis of HCC has been widely considered to be rare, the confirmation of effective therapy is awaited because histological studies have suggested that this pathologic lesion may occur more often than expected.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnostic Imaging. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Silicates / administration & dosage. Titanium / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262054.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 26
  •  go-up   go-down


3. Kadono K, Kawamoto K, Park T: [A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2661-3
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy].
  • CT demonstrated intra-abdominal lymph node enlargement 2 years postoperatively and CA19-9 increased.
  • S-1, an oral fluoropyrimidine anticancer drug, was started as first-line chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Drug Combinations. Humans. Male. Neoplasm Recurrence, Local. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009476.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


Advertisement
4. Aydin C, Unalp HR, Baloğlu A, Inci AG, Yiğit S, Yavuzcan A: Axillary lymph node metastasis from serous ovarian cancer: a case report and review of the literature. Arch Gynecol Obstet; 2009 Feb;279(2):203-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary lymph node metastasis from serous ovarian cancer: a case report and review of the literature.
  • INTRODUCTION: The symptoms and findings of ovarian cancer are parallel with the degree of intra-abdominal expansion of the tumor.
  • Renal and cerebral metastases of ovarian cancer have been previously reported, but axillary lymph node metastasis is quite rare.
  • Axillary lymph node metastasis usually occurs in the advanced stage.
  • MATERIALS AND METHODS: We present a 47-year-old female who had applied adjuvant chemotherapy following cyto-reductive surgery because of stage 3C ovarian cancer.
  • Axillary lymph node metastasis was detected in the postoperative 32 months.
  • CONCLUSION: As tumors in axillary lymph nodes are found in patients with an ovarian carcinoma, the treatment is also so important too.
  • Metastasis to the breast be differentiated accurately from primary breast cancer, because prognosis and treatment differ significantly.
  • Accurate diagnosis of these metastases may allow more appropriate therapy, such as chemotherapy, and prevent the patient from an unnecessary major breast surgery.
  • [MeSH-major] Axilla. Lymphatic Metastasis / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470522.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 24
  •  go-up   go-down


5. Hasuike Y, Takeda Y, Ueda S, Tujinaka T, Yoshida K: [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2433-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
  • She developed abdominal pain.
  • CT scans showed a low-density area in the lateral segment of the liver and lymph node swelling to the left of the abdominal aorta.
  • She underwent further liver resection and microwave coagulation therapy.
  • At that time, lymph node biopsy confirmed metastatic carcinoid.
  • We began hepatic arterial chemotherapy for the residual liver and radiation therapy for the para-aortic lymph nodes (total 45 Gy).
  • During chemotherapy, no recurrence was seen.
  • [MeSH-major] Carcinoid Tumor / therapy. Liver Neoplasms / therapy. Lymphatic Metastasis / pathology
  • [MeSH-minor] Combined Modality Therapy. Doxorubicin / administration & dosage. Electrocoagulation. Female. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Microwaves / therapeutic use. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Okamura S, Nakata K, Suzuki R, Uji K, Yoshida A, Yoshimura M, Okada K, Nakahira S, Miki H, Sugimoto K, Tamura S: [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2168-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].
  • A 60-year-old man diagnosed as advanced sigmoid colon cancer was performed sigmoidectomy and D3 lymph node dissection.
  • Intra-operative findings were SE, P0H1N4M (-), and Stage IV.
  • One month after the operation, we started a combination chemotherapy using S-1 plus CPT-11 as one course for five weeks.
  • A Follow-up abdominal CT scan revealed a drastic reduction of liver metastasis and disappearance of para-aortic lymph node swelling (PR in).
  • The combination chemotherapy was once finished after eight courses due to the patient's request.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Sigmoid Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106559.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Ho CM, Chien TY, Shih BY, Huang SH: Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol; 2003 Mar;88(3):394-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.
  • OBJECTIVE: The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
  • METHODS: Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997-2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy.
  • Group B (8 patients, 1991-1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy.
  • The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy.
  • Median time to recurrence was 8 months.
  • CONCLUSIONS: Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aorta. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pelvis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648592.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Depending on the tumor location and vascularization, a fluoroscopy catheter was placed either in the abdominal aorta or internal pelvic artery.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • In the case of radiological response and clinical progression or clinical response and radiological progression, therapy was continued.
  • Therapy could be stopped by the patient at any time.
  • RESULTS: Treatment was tolerated well by all patients.
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


9. Hirayama Y, Kubota M, Imamura M, Imai C, Okuyama N, Tsukada M, Kobayashi K, Sato K, Takachi T, Iwavuchi H, Uchiyama M: A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis. J Pediatr Surg; 2009 Dec;44(12):2395-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis.
  • We, herein, report the case of a 2-year-old boy who presented with a huge yolk sac tumor with retroperitoneal lymph nodes metastasis that originated in a left intra-abdominal undescended testis.
  • Computed tomography and magnetic resonance imaging showed a huge round tumor connecting to the left retroperitoneal lymph nodes with metastasis extending from the left pelvic region to the left renal hilum.
  • The right abdominal tumor appeared to be a giant testis that had strangulated at the neck of the cord.
  • The tumor had ruptured at the side of the left pelvic lymph node metastasis, and a yolk sac tumor was diagnosed from a histologic analysis of the resected specimens.
  • Postoperative PEB chemotherapy was effective, and a complete surgical resection of the tumor was performed 3 months after the initial laparotomy.
  • The pathologic findings showed fibrous tissue without any tumor cells.
  • This case might be a coincidental association of a yolk sac tumor occurring in an undescended testis, which thus caused a delay in making an accurate diagnosis.
  • [MeSH-major] Cryptorchidism / diagnosis. Endodermal Sinus Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] CA-125 Antigen / blood. Child, Preschool. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Staging. Preoperative Care. Retroperitoneal Neoplasms / secondary. Testis / pathology. Testis / surgery. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006035.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Mori Y, Katsumata K, Tokita H, Kato F, Yamamoto J, Tsuchida A, Aoki T: [A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1485-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
  • The patient was a 70-year-old man who in November 2000 had undergone pancreatoduodenectomy for a diagnosis of lower bile duct cancer by his previous physician.
  • Left cervical and intra-abdominal lymph node enlargement were detected at 3 years 4 months postoperatively, and a biopsy resulted in a histopathological diagnosis of metastasis by bile duct cancer.
  • S-1/CDDP therapy seemed to be capable of serving as a useful treatment for gallbladder and bile duct cancer in the future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Humans. Lymphatic Metastasis / pathology. Male. Oxonic Acid / administration & dosage. Pancreaticoduodenectomy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876152.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Small W Jr, Mahadevan A, Roland P, Vallow L, Zusag T, Fishman D, Massad S, Rademaker A, Kalapurakal JA, Chang S, Lurain J: Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Cancer J; 2000 Nov-Dec;6(6):394-400

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival.
  • PURPOSE: The purpose of this study was to determine the toxicity, patterns of recurrence, and survival in high-risk endometrial cancer patients treated with whole-abdominal radiation.
  • Patients believed to be at high risk for intra-abdominal recurrence and who received whole-abdominal radiation were reviewed for this study.
  • RESULTS: A total of 30 patients completed whole-abdominal radiation (WAR) and were available for study.
  • Seventy-eight percent of the cohort received surgical staging with bilateral salpingo-oophorectomy/total abdominal hysterectomy/lymph node sampling.
  • Megestrol acetate (Megace) was used as an adjuvant treatment in 37% of patients, and no cases received initial chemotherapy.
  • The pattern of first recurrence was 0% in the vaginal cuff, 3% other vaginal, 7% pelvic, 7% upper abdominal, 3% lung, 7% bone, and 7% para-aortic lymph nodes.
  • CONCLUSIONS: Utilizing a conservatrive total whole-abdominal radiation dose and limited para-aortic nodal boost resulted in very tolerable treatments.
  • [MeSH-major] Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Endometrial Neoplasms / radiotherapy. Neoplasm, Residual / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Papillary. Brachytherapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131490.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Iwauchi T, Amano R, Ohira G, Nakamoto K, Doi Y, Yamada N, Ohira M, Hirakawa K: [A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2373-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 70s woman was referred to our hospital for treatment of a pancreatic head cancer in November 2007.
  • Adjuvant chemotherapy of UFT was administered one month after operation.
  • However, a second chemotherapy of S-1 was administered because DUPAN-2 levels showed a high range 8 months after operation.
  • Ten months after operation, abdominal computed tomography demonstrated a 2 cm tumor in the liver.
  • Then, hepatic arterial infusion (HAI) chemotherapy of 5-FU/CDDP was instituted weekly.
  • We suggest that HAI chemotherapy of 5-FU+CDDP might be an effective treatment to liver metastasis of pancreatic cancer and prolong prognosis of those patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Drug Resistance, Neoplasm. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Lymph Node Excision. Oxonic Acid / administration & dosage. Pancreaticoduodenectomy. Tegafur / administration & dosage


13. Xing PY, Shi YK, Feng FY, Qin Y, Liu P: [Clinical characteristics and treatment of desmoplastic small round cell tumor]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):139-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment of desmoplastic small round cell tumor].
  • OBJECTIVE: To investigate the clinical characteristics and treatment of desmoplastic small round cell tumor.
  • RESULTS: The median age of all cases was 23 (1.5 - 66) years old at the time of diagnosis.
  • The most common presenting complaint was intra-abdominal mass or pain (77.4%).
  • Fifteen (28.3%) had positive lymph nodes or distant parenchymal metastases.
  • Thirty-four patients received chemotherapy and the 1- and 3-year survival rates were 60.1% and 35.2%, respectively, however, only 29.7% and 12.7% in patients without chemotherapy (P = 0.0396).
  • Chemotherapy and radiotherapy correlate with improved patient outcome.
  • Multimodal therapy may improve the survival in patients with DSRCT.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / therapy. Desmoplastic Small Round Cell Tumor / pathology. Desmoplastic Small Round Cell Tumor / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Radiotherapy, Conformal. Surgical Procedures, Operative. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403246.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; IVAD protocol
  •  go-up   go-down


14. Goldstein NS, Ceniza N: Ovarian micropapillary serous borderline tumors. Clinicopathologic features and outcome of seven surgically staged patients. Am J Clin Pathol; 2000 Sep;114(3):380-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the MSBTs had microinvasion in the ovarian neoplasm.
  • The MSBT pattern constituted 25% to almost all of the neoplasm.
  • Four patients were alive and well at the last follow-up visit, including 1 patient with stage IIIC (lymph node metastases) disease who had noninvasive implants (12 years after surgery).
  • One patient who was free of disease died of complications of chemotherapy and abdominal surgery.
  • Two patients died of intra-abdominal neoplastic growth (stages IIC and IIIB) 5 and 9 years after surgery, respectively; both had invasive implants.
  • Pathologists should recognize MSBT as a neoplasm that can have adverse prognostic features, including invasive peritoneal implants.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10989638.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Turial S, Karabul N, Gutjahr P, Engel V, Bierschock S, Schier F: Ovarian tumours: late extramedullary recurrence of acute leukaemia. Eur J Pediatr Surg; 2009 Jun;19(3):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local therapy such as irradiation or extensive surgical resection of the mass is ineffective and unnecessary.
  • Treatment was initiated according to the CoALL 82-protocol.
  • At the age of 11, the girl presented with a huge abdominal mass.
  • Chemotherapy and low-dose radiotherapy succeeded in shrinking the tumour mass, making it operable.
  • Subsequently, she developed a painless abdominal tumour.
  • Laparoscopic lymph node staging was performed and biopsies were taken.
  • Chemotherapy was initiated according to the BFM protocol for ALL recurrence.
  • CONCLUSION: Because we experienced favourable results with laparoscopic biopsy in our patients, we are of the opinion that laparoscopy-assisted biopsies are well suited for the management of intra-abdominal tumours in systemic malignant disease.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Humans. Ovariectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212934.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Fabozzi M, Allieta R, Brachet Contul R, Grivon M, Millo P, Lale-Murix E, Nardi M Jr: Comparison of short- and medium-term results between laparoscopically assisted and totally laparoscopic right hemicolectomy: a case-control study. Surg Endosc; 2010 Sep;24(9):2085-91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study aimed to compare the short- and medium-term results obtained by totally laparoscopic right colectomy (TL) with those obtained by laparoscopically assisted right colectomy (LAC) for the treatment of right colon cancer.
  • The study outcomes included operative time, length of minilaparotomy, intraoperative complications, postoperative pain, time to resumption of the gastrointestinal functions, permanence of abdominal drain, analgesic therapy duration, postoperative complications, hospitalization time, number of harvested lymph nodes, and distant metastases onset.
  • RESULTS: The mean operative times were 78 ± 25 min (TL group) and 92 ± 22 min (LAC group) (p < 0.05).
  • No complications occurred either intra- or postoperatively, and similarly, the TL group experienced no mortality.
  • The limits of this retrospective comparative study do not allow definitive conclusions to be drawn despite the encouraging data for the next prospective randomized studies.
  • [MeSH-minor] Analgesics / therapeutic use. Drainage / methods. Female. Humans. Intraoperative Complications. Length of Stay / statistics & numerical data. Lymph Node Excision. Male. Middle Aged. Neoplasm Metastasis. Pain, Postoperative / drug therapy. Postoperative Complications. Recovery of Function. Retrospective Studies. Statistics, Nonparametric. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 Jan;10(1):44-52 [19071061.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):323-6 [15637736.001]
  • [Cites] Surgery. 2006 Oct;140(4):675-82; discussion 682-3 [17011916.001]
  • [Cites] Dis Colon Rectum. 2006 Apr;49(4):464-9 [16518715.001]
  • [Cites] World J Surg Oncol. 2007 May 11;5:49 [17498289.001]
  • [Cites] World J Surg. 2008 Jun;32(6):1138-41 [18404288.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1769-80 [18437486.001]
  • [Cites] Minerva Chir. 2003 Aug;58(4):621-7 [14603179.001]
  • [Cites] Curr Opin Crit Care. 2009 Aug;15(4):355-8 [19617822.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1878-9 [17377832.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1603-8 [19452217.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):630-41 [12095591.001]
  • [Cites] Surg Radiol Anat. 2003 May;25(2):86-8 [12802511.001]
  • [Cites] Surg Clin North Am. 2008 Oct;88(5):1047-72, vii [18790154.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):728-33 [17968162.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1350-5 [18478297.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]
  • [Cites] Bull Cancer. 2007 Dec;94(12):1053-8 [18156112.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003432 [18425886.001]
  • [Cites] Chir Ital. 2008 Jan-Feb;60(1):1-7 [18389741.001]
  • (PMID = 20174945.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


17. Neumann G, Rasmussen KL, Petersen LK: Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. Obstet Gynecol; 2007 Aug;110(2 Pt 2):467-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 35-year-old woman with cervical adenosquamous carcinoma diagnosed during delivery was treated with radical abdominal hysterectomy with bilateral pelvic lymphadenectomy.
  • Five weeks later the metastatic tumor at the episiotomy site was excised, and the patient received adjuvant chemotherapy and radiation therapy.
  • Relapse occurred rapidly, and surgical exenteration was initiated but abandoned intraoperatively due to the presence of intra-abdominal carcinomatosis.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / pathology. Puerperal Disorders / therapy


18. Mita Y, Ajiki T, Kamigaki T, Okazaki T, Hori H, Horiuchi H, Hirata K, Fujita T, Fujimori T, Kuroda Y: Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice. Ann Surg Oncol; 2007 Apr;14(4):1374-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis of gallbladder carcinoma is poor; therefore, investigating the efficacy of new chemotherapy agents is essential for the treatments for this tumor.
  • Recently, several studies have reported clinical trials using gemcitabine as treatment for advanced gallbladder cancers.
  • One week after transplantation, the mice were randomized into two groups: In Group A, the mice were treated by an intra-peritoneal injection of 0.9% sodium chloride for three weeks after inoculation (control).
  • In Group B, the mice were treated by an intra-peritoneal injection of gemcitabine (125 mg / kg) for three weeks.
  • All mice were sacrificed one week after the end of treatment, and macroscopic and histological findings were evaluated.
  • Survival duration of the mice after gemcitabine treatment was compared to that of untreated mice.
  • In the in vivo models, the Group A mice showed huge tumors of the gallbladder, with liver invasion and lymph node metastases.
  • However, there were no abdominal tumors in the Group B mice, and microscopic gallbladder cancer could only be detected from histological findings.
  • CONCLUSIONS: Gemcitabine treatment may inhibit tumor progression and prolong survival in gallbladder cancer by inhibiting cell proliferation and inducing apoptosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Animals. Apoptosis. Cell Proliferation. Humans. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis / prevention & control. Proliferating Cell Nuclear Antigen / metabolism. Survival Rate. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235714.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Proliferating Cell Nuclear Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


19. Akcali Z, Ozyilkan O, Sakalli H, Bal N, Noyan T: Gallbladder adenosquamous cell carcinoma: report of two cases. Acta Gastroenterol Belg; 2005 Oct-Dec;68(4):440-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenosquamous cell carcinoma accounts for less than 3.5% of gallbladder carcinomas, and is characterised by invasive growth, a reduced tendency for lymph node metastasis, an increased tendency for hepatic infiltration or liver metastasis, and a poorer prognosis than adenocarcinoma.
  • The first patient presented to our institution with increased bilirubin levels and dilated intra- and extrahepatic bile ducts.
  • After surgery, bilirubin levels decreased, but hepatic metastases occurred that did not respond to conventional chemotherapy.
  • The second patient was admitted to our hospital with jaundice and abdominal pain.
  • Abdominal computed tomography (CT) imaging showed marked thickening of the gallbladder with direct extension of a mass into the left liver lobe.
  • Cytology specimens obtained with an endoscopic retrograde cholangiopancreatography (ERCP) procedure revealed a malignant epithelial tumour.
  • A regimen of oral UFT (Tegafur + uracil) chemotherapy was begun.
  • Serum bilirubin levels increased due to occlusion in the surgical area 15 weeks after the start of chemotherapy.
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde / methods. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Tegafur / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432998.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Wu K, Zhang WH, Zhang R, Li H, Bai P, Li XG: [Analysis of postoperative complications of radical hysterectomy for 219 cervical cancer patients]. Zhonghua Zhong Liu Za Zhi; 2006 Apr;28(4):316-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the causes and therapeutic approaches for the complications of radical hysterectomy plus pelvic lymphadenectomy in cervical cancer patients.
  • RESULTS: a total of 49 patients (22.4%) developed postoperative complications.
  • The postoperative complication incidence in the patients who had preoperative neoadjuvant chemotherapy through intra-arterial catheter or radical radiotherapy in the other hospitals were 50.0% (2/4) and 100.0% (1/1), which were higher than that of the patients treated primarily in our hospital (21.3%, 25.3%) though without statistically significant difference among the groups.
  • Of 52 patients who had previous abdominal surgery history, 13 developed posoperative complications, there was no significant difference between the patients with or without previous abdominal surgery history.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hysterectomy / adverse effects. Lymph Node Excision. Urinary Retention / etiology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Brachytherapy / adverse effects. Female. Humans. Lymphocele / etiology. Middle Aged. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects


21. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • A 66-year-old man was admitted to our hospital because of an intra-abdominal tumor and pleural effusion (PE).
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


22. Lefor AT: Laparoscopic interventions in lymphoma management. Semin Laparosc Surg; 2000 Jun;7(2):129-39
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of the surgeon in the care of the patient with lymphoma is limited mostly to obtaining a diagnosis.
  • Laparoscopy can play a significant role in the care of the patient requiring accurate intra-abdominal staging.
  • The staging procedure is conducted in a fashion identical to the open procedure, including multiple liver biopsies, a splenectomy, and multiple lymph node biopsies.
  • Patients with non-Hodgkin's lymphoma almost never require staging, and laparoscopy may play a role in obtaining tissue for diagnosis in a small fraction of patients.
  • Patients with Hodgkin's disease who have diffuse disease (stages III and IV) never need staging because they will all receive chemotherapy.
  • Likewise, patients with limited disease (stage I) are usually treated with radiation therapy alone.
  • The laparoscopic approach to this procedure may afford benefits to the patient including decreased hospitalization, morbidity, and reduced delays in obtaining definitive treatment.
  • [MeSH-minor] Humans. Neoplasm Staging. Splenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11320483.001).
  • [ISSN] 1071-5517
  • [Journal-full-title] Seminars in laparoscopic surgery
  • [ISO-abbreviation] Semin Laparosc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


24. Oida Y, Motojuku M, Morikawa G, Mukai M, Imaizumi T, Makuuchi H: [A case of advanced gastric cancer effectively treated with combination of weekly paclitaxel and hepatic arterial infusion of 5-FU/LV]. Gan To Kagaku Ryoho; 2008 Feb;35(2):303-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 66-year-old woman who underwent upper gastrointestinal endoscopy as part of a detailed examination because of loss of appetite and anemia, and type 2 gastric cancer was detected on the greater curvature in the pyloric area.
  • Abdominal ultrasonography and CT revealed lymph node enlargement around the pyloric area and multiple liver metastases in both lobes of the liver.
  • Curative resection was judged to be impossible, and oral S-1 therapy was started.
  • However, no efficacy was observed even after the completion of three courses, and especially because of the rapid increase in the size of the liver metastases, treatment was switched to combination therapy consisting of a continuous hepatic artery infusion of 5-FU+Leucovorin (day 1-7) and weekly PTX for 3 consecutive weeks (day 8, 15, 22) followed by a 1-week rest.
  • The tumor marker levels decreased rapidly, and at the end of 4 courses marked regression of the primary tumor and lymph node metastases as well as of the metastatic foci in the liver was observed.
  • Adverse events have been mild, and at present, 6 months after the switch in treatment, good QOL has been maintained, and treatment is continuing.
  • This method appears to be an effective treatment strategy for unresectable advanced gastric cancer complicated by liver metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Liver Neoplasms / blood supply. Liver Neoplasms / drug therapy. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Female. Gastroscopy. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281770.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; P88XT4IS4D / Paclitaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Kohya N, Hashiguchi K, Yakabe T, Miyoshi A, Ohtsuka T, Kitahara K, Miyazaki K: [A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1753-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal CT scan showed a dilatation of the intra-hepatic bile duct and a tumor around hilar bile duct.
  • We diagnosed it as hilar bile duct carcinoma, and although we operated it was unresectable because of the metastasis of a para-aorta lymph node and duodenal invasion.
  • We started chemo-radiotherapy with a total dose of 45 Gy and gemcitabine.
  • The tumor and para-aorta lymph node were remarkably decreased, and tumor marker CA 19-9 was also decreased to within the normal range.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / radiography. Duodenal Neoplasms / secondary. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838042.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement